| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Candidiasis, Oral | D002180 | 11 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Fibrosis | D005355 | 23 associated lipids |
| Glioblastoma | D005909 | 27 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Hypergammaglobulinemia | D006942 | 9 associated lipids |
| Insulin Resistance | D007333 | 99 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Nephritis | D009393 | 19 associated lipids |
| Neurilemmoma | D009442 | 10 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Thyroid Neoplasms | D013964 | 33 associated lipids |
(e,z)-farnesol
(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol
PubChem Biomolecular Interactions and Pathways
All references with (e,z)-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Colabardini AC et al. | Involvement of the Aspergillus nidulans protein kinase C with farnesol tolerance is related to the unfolded protein response. | 2010 | Mol. Microbiol. | pmid:21091509 |
| Savoldi M et al. | Farnesol induces the transcriptional accumulation of the Aspergillus nidulans Apoptosis-Inducing Factor (AIF)-like mitochondrial oxidoreductase. | 2008 | Mol. Microbiol. | pmid:18681941 |
| Bai C et al. | Characterization of a hyperactive Cyr1 mutant reveals new regulatory mechanisms for cellular cAMP levels in Candida albicans. | 2011 | Mol. Microbiol. | pmid:21992526 |
| Hogan DA et al. | A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. | 2004 | Mol. Microbiol. | pmid:15554963 |
| Dichtl K et al. | Farnesol misplaces tip-localized Rho proteins and inhibits cell wall integrity signalling in Aspergillus fumigatus. | 2010 | Mol. Microbiol. | pmid:20398212 |
| Funari SS et al. | Farnesol and geranylgeraniol modulate the structural properties of phosphatidylethanolamine model membranes. | 2005 Jul-Aug | Mol. Membr. Biol. | pmid:16154902 |
| Halaschek-Wiener J et al. | A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. | 2000 | Mol. Med. | pmid:11055588 |
| McMahon LP et al. | Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. | 2005 | Mol. Endocrinol. | pmid:15459249 |
| Cox AD et al. | Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. | 1992 | Mol. Cell. Biol. | pmid:1375323 |
| Lagace TA et al. | Caspase processing and nuclear export of CTP:phosphocholine cytidylyltransferase alpha during farnesol-induced apoptosis. | 2002 | Mol. Cell. Biol. | pmid:12052891 |
| Ferdinandy P et al. | Rapid pacing-induced preconditioning is recaptured by farnesol treatment in hearts of cholesterol-fed rats: role of polyprenyl derivatives and nitric oxide. | 1998 | Mol. Cell. Biochem. | pmid:9774182 |
| Léger T et al. | The Metacaspase (Mca1p) Restricts O-glycosylation During Farnesol-induced Apoptosis in Candida albicans. | 2016 | Mol. Cell Proteomics | pmid:27125826 |
| Léger T et al. | The metacaspase (Mca1p) has a dual role in farnesol-induced apoptosis in Candida albicans. | 2015 | Mol. Cell Proteomics | pmid:25348831 |
| Ura H et al. | Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. | 1998 | Mol. Carcinog. | pmid:9496909 |
| Stärkel P et al. | Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. | 2012 | Mol. Carcinog. | pmid:21882255 |
| Levy R et al. | Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas. | 2010 | Mol. Cancer Ther. | pmid:20682656 |
| Barkan B et al. | Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling. | 2011 | Mol. Cancer Ther. | pmid:21632464 |
| Goldberg L et al. | Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats. | 2008 | Mol. Cancer Ther. | pmid:19001442 |
| Zundelevich A et al. | Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). | 2007 | Mol. Cancer Ther. | pmid:17541036 |
| Blum R et al. | Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. | 2006 | Mol. Cancer Ther. | pmid:16985068 |